Hasil Pencarian - Eva Arranz

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation

    A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation oleh Paola Villafuerte-Gutiérrez, Montserrat López Rubio, Pilar Herrera, Eva Arranz

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.

    Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase. oleh Álvaro Cuesta-Domínguez, Mara Ortega, Cristina Ormazábal, Matilde Santos-Roncero, Marta Galán-Díez, Juan Luis Steegmann, Ángela Figuera, Eva Arranz, José Luis Vizmanos, Juan A Bueren, Paula Río, Elena Fernández-Ruiz

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Jumping Translocation in a Patient with Acute Leukemia and Fatal Evolution

    Jumping Translocation in a Patient with Acute Leukemia and Fatal Evolution oleh Irene Sánchez Prieto, Montserrat López Rubio, Eva Arranz, Rosa Ayala, Marta Callejas Charavía, Yolanda Martín Guerrero, Juan José Gil Fernández, Susana Valenciano Martínez, Lucía Castilla García, María Argüello Marina, José María Aspa Cilleruelo, Celia Martínez Vázquez, Julio García Suárez

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

    First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle... oleh Reyes Arranz, Ana García-Noblejas, Carlos Grande, Jimena Cannata-Ortiz, José J. Sánchez, José-Antonio García-Marco, Concepción Aláez, Javier Pérez-Calvo, Pilar Martínez-Sánchez, Blanca Sánchez-González, Miguel-Angel Canales, Eulogio Conde, Alejandro Martín, Eva Arranz, María-José Terol, Antonio Salar, Dolores Caballero

    Diterbitkan 2013-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-

    Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q- oleh Mar Mallo, Leonor Arenillas, Blanca Espinet, Marta Salido, Jesús Mª Hernández, Eva Lumbreras, Mónica del Rey, Eva Arranz, Soraya Ramiro, Patricia Font, Olga González, Mónica Renedo, José Cervera, Esperanza Such, Guillermo F. Sanz, Elisa Luño, Carmen Sanzo, Miriam González, María José Calasanz, José Mayans, Carlos García-Ballesteros, Victoria Amigo, Rosa Collado, Isabel Oliver, Félix Carbonell, Encarna Bureo, Andrés Insunza, Lucrecia Yañez, María José Muruzabal, Elena Gómez-Beltrán, Rafael Andreu, Pilar León, Valle Gómez, Ángeles Sanz, Natalia Casasola, Esperanza Moreno, Adrián Alegre, María Luisa Martín, Carmen Pedro, Sergi Serrano, Lourdes Florensa, Francesc Solé

    Diterbitkan 2008-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: